Survey: Did the FDA Jump the Gun?

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The newest generic OTC nonprescription naloxone hydrochloride nasal spray provides additional access to the lifesaving treatment, at potentially lower cost.

October 25th 2023

Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

August 30th 2023

FDA Approves First New Antibiotic in Decades for Uncomplicated UTI

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Food vs Medicine for IBS: Dietary Measures First, New Study Suggests

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

FDA Approves Second Generic OTC Naloxone Nasal Spray to Reverse Opioid Overdose

More participants consuming either of 2 common IBS dietary regimens experienced significant and sustained symptom relief vs those given pharmacotherapy.

Related Content

April 26th 2024

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The newest generic OTC nonprescription naloxone hydrochloride nasal spray provides additional access to the lifesaving treatment, at potentially lower cost.

October 25th 2023

Adults with Obesity Who Receive Semaglutide as First Weight Loss Medication Lose More Weight

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

August 30th 2023

FDA Approves First New Antibiotic in Decades for Uncomplicated UTI

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Food vs Medicine for IBS: Dietary Measures First, New Study Suggests

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.